MedTrace Logo

Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth

NCT07464886 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-03-11

No results posted yet for this study

Summary

The primary goal is to investigate to what extent changes in glutamate and glutathione modulation and functional integration between brain networks associated with emotion and attention regulation are associated with treatment response in mildly depressed youth.

Conditions

  • Mild Depression

Interventions

DRUG

N-acetylcysteine

N-acetylcysteine 2400 mg/d

BEHAVIORAL

Mindfulness-based cognitive therapy

Mindfulness-based cognitive therapy

DRUG

Placebo

Placebo capsules

BEHAVIORAL

Sham mindfulness-based intervention

Sham mindfulness-based intervention

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • University of Cincinnati

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-26
Primary Completion
2030-03-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07464886 on ClinicalTrials.gov